Neurohormonal blockade in chronic heart failure How much is enough? can there be too much?∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Massie, Barry M
EDITORIAL COMMENT
Neurohormonal Blockade
in Chronic Heart Failure
How Much Is Enough?
Can There Be Too Much?*
Barry M. Massie, MD
San Francisco, California
For nearly 20 years, research studies into the pathophysiol-
ogy of chronic heart failure (CHF) and its treatment have
focused on the role of neurohormonal activation and its
blockade (1,2). Initially, the increased activity of multiple
neurohormonal systems in CHF was considered a poten-
tially important compensatory response to the underlying
hemodynamic abnormalities. Subsequently, the potentially
deleterious consequences of neurohormonal activation and
its association with a poorer prognosis became apparent.
However, it was only with the recognition of the remarkable
benefits of inhibition of the renin-angiotensin-aldosterone
system and, subsequently, the adrenergic nervous system
that the paradigm of neurohormonal activation and its
downstream consequences of cytokine activation, apoptosis
and myocardial remodeling became the dominant paradigm
for understanding the mechanisms of progression of CHF
and for developing new interventions to alter the natural
history of this condition.
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The pace of research in this area has been extraordinarily
rapid, but few basic or clinical studies have examined the
“dose-response” characteristics of either blockade of a single
neurohormonal system or the cumulative effects of blocking
multiple systems. Therefore, it has been assumed that
higher doses of agents such as angiotensin-converting en-
zyme (ACE) inhibitors would be more effective than lower
doses and that combination therapy with agents that pro-
duce more complete neurohormonal blockade would be
associated with better outcomes. Indeed, the widespread use
of ACE inhibitors in doses substantially below those found
effective in clinical trials had been considered a target for
quality improvement initiatives (3). Until relatively recently,
few studies have contradicted these notions, and several
observations provide indirect justification for the use of
high-dose ACE inhibitors or combinations of neurohor-
monal antagonists. In particular, it is known that during
chronic therapy with usual doses of ACE inhibitors, both
angiotensin-II and aldosterone levels initially are lowered
but subsequently “escape” to levels approaching pretreatment
values (4–6). This may represent inadequate inhibition of
ACE activity, alternative pathways for angiotensin-II genera-
tion, and/or the effect of nonangiotensin-II regulation of
aldosterone secretion. Persistently elevated aldosterone lev-
els, in particular, may play an important role in adverse
cardiac remodeling (7). Furthermore, ACE inhibition has at
best relatively minor long-term effects on plasma cat-
echolamines (8,9).
HIGH- VERSUS LOW-DOSE ACE INHIBITOR THERAPY
The study reported by Tang et al. (10) in this issue of the
Journal represents an ambitious effort to evaluate whether
high or low doses of an ACE inhibitor produce greater
neurohormonal suppression, changes in left ventricular
structure and function, improvements in exercise tolerance,
and clinical benefit. Seventy-five patients with ejection
fractions 40% were randomized to enalapril 40 mg or
5 mg once daily and evaluated over a period of 30 weeks. At
the end of the follow-up period there was greater suppres-
sion of serum ACE activity (and in a subgroup of 17
subjects, myocardial ACE activity) in the high-dose group,
but no differences in measurements of angiotensin-II, aldo-
sterone or catecholamines. There were only modest changes
in New York Heart Association (NYHA) functional class,
exercise tolerance and left ventricular function, with no
intergroup differences. However, a composite clinical end
point of death, hospitalizations, emergency room visits and
need for sustained increases in diuretic dose occurred in
fewer patients in the high-dose group (30% vs. 53%, p 
0.061). Perhaps the most clear and mechanistically impor-
tant finding of this study is that high-dose therapy had no
greater effect on the key neurohormonal measurements—
angiotensin-II, aldosterone or catecholamines—than low-
dose treatment. Unfortunately, the relatively small numbers
of subjects, withdrawal of 25 of 75 patients, and limited
period of follow-up preclude determination of whether
there were differences in left ventricular size and clinical
outcomes, both of which trended in favor of high-dose
therapy. Thus, this study does not exclude the possibility
that high doses of ACE inhibitors are superior to low doses,
but it does suggest that differences are not likely to be
dramatic.
This conclusion is consistent with the results of the
Assessment of Treatment with Lisinopril And Survival
(ATLAS) trial (11). In that study, 3,164 patients with
symptomatic heart failure and left ventricular ejection frac-
tion 30% were randomized to a high (target dose 35 mg
once daily) or low dose (2.5 or 5 mg once daily) lisinopril
therapy. The high-dose group had a nonsignificant 8%
lower risk of death, the primary end point (p  0.128), but
a significant 12% lower risk of death or hospitalization for
any reason (p  0.002) and a 24% reduction in heart failure
hospitalizations (p  0.002). In this much larger and longer
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study, the advantage of high-dose ACE inhibitor therapy
was modest and would probably have been considerably
smaller had the high dose been compared to the recom-
mended doses of other ACE inhibitors (lisinopril 20 mg
daily, enalapril 10 mg twice daily or captopril 50 mg three
times daily).
ARE TWO NEUROHORMONAL
ANTAGONISTS BETTER THAN ONE?
The findings of a number of trials, involving well over
10,000 CHF patients, have clearly demonstrated that the
addition of three different beta-blockers (carvedilol, biso-
prolol and metoprolol) to ACE inhibitors reduce mortality
by 30% to 35% and heart failure hospitalizations by a similar
amount (12–15). Unfortunately, trials have not been con-
ducted to establish that ACE inhibitors provide important
additional benefit when added to beta-blockers, and such
trials are unlikely to be done in symptomatic heart failure
patients. However, one would expect significant additivity,
and such has been the case in beta-blocked postmyocardial
infarction patients with reduced ejection fractions (16).
Thus, a combination of an ACE inhibitor and a beta-
blocker is now the standard of care for most CHF patients
(17,18).
Whether spironolactone, an aldosterone receptor blocker,
could improve the outcomes of patients receiving typical
doses of ACE inhibitors was addressed in patients with very
severe CHF (NYHA functional class IV at entry or in the
prior six months) in the Randomized Aldactone Longevity
Evaluation Study (RALES) (19). This hypothesis was based
upon the previously discussed escape of aldosterone during
chronic ACE inhibition and the deleterious effect of this
hormone on myocardial remodeling in animals (7,8). How-
ever, the magnitude of the benefit probably surprised even
the investigators, with the trial being discontinued early as a
result of a 30% reduction in mortality and a 35% reduction
in heart failure hospitalizations in the spironolactone group.
The picture is much less clear when an angiotensin
receptor blocker is added in patients receiving an ACE
inhibitor. Again, benefit might be anticipated, because
angiotensin-II levels remain elevated in many patients who
are on ACE inhibitors. Furthermore, addition of an angio-
tensin receptor blocker has been associated with improve-
ments in both hemodynamic measurements (20) and exer-
cise tolerance (21). However, in a pilot study comparing
candesartan in several doses either alone or in combination
with enalapril or with enalapril alone, there was no sustained
reduction on aldosterone or norepinephrine (22). Clinical
events (death or the composite of death plus heart failure
hospitalization) trended lower on enalapril alone compared
to the combination, although the numbers are too small to
reach any conclusions. The hypothesis that addition of an
angiotensin receptor blocker to ACE inhibitor could im-
prove outcomes was addressed in the Valsartan Heart
Failure Trial (Val-HeFT) (23), which enrolled 5,010 pa-
tients with NYHA functional class II to IV CHF, left
ventricular ejection fraction 40% and left ventricular
dilation, of whom 93% were receiving ACE inhibitors. Two
co-primary end points, mortality and the composite of
mortality and morbidity (primarily hospitalization for wors-
ening heart failure), were examined. Preliminary results of
this trial indicated that the addition of valsartan has a
neutral effect on mortality (relative risk [RR] 1.02, p 
0.80), but was associated with a modest benefit on the
composite mortality and morbidity end point (RR 0.87, p
0.009). However, in a prespecified subgroup analyses this
benefit was greatest in the 7% of patients who were not
taking ACE inhibitors and was no longer statistically
significant among those who were on combination therapy.
Thus, the combination of an angiotensin receptor blocker
and ACE inhibitor seems to be at best marginally superior
to an ACE inhibitor alone, although this issue is being
addressed again in the ongoing Candesartan Cilexitil in
Heart Failure Assessment of Reduction in Mortality and
Morbidity (CHARM) and Valsartan in Acute Myocardial
Infarction (VALIANT) trials (24,25).
ARE THREE NEUROHORMONAL
ANTAGONISTS BETTER THAN TWO?
Because the combination of ACE inhibitors and beta-
blockers is now recommended for most CHF patients with
systolic dysfunction, the relevant question has become
whether adding a third neurohormonal antagonist is desir-
able. Again, the evidence is mixed. In RALES, 10% of the
participants were receiving a beta-blocker as well as an ACE
inhibitor (19). The mortality reduction in his subgroup was
58% compared to 28% in those who were not taking
beta-blockers. The number of patients in this subgroup was
small and the interaction was not statistically significant;
nonetheless, this finding suggests that more neurohormonal
antagonism may have something to offer. However, there
are two important provisos. First, the patients entered into
RALES had more severe heart failure as indicated by their
recent NYHA functional class IV status and the 23% annual
mortality rate in the placebo group, and they also required
treatment with loop diuretics, usually in high doses. Thus,
as a group they probably had marked neurohormonal
activation. Second, one cannot assume that agents that
block other hormones would have similar additivity.
Of the Val-HeFT subjects, 35% were on beta-blockers as
well as ACE inhibitors, and there was a significant inter-
action between valsartan effect and background beta-blocker
therapy (23). Although as noted above, valsartan was
associated with a 13% reduction in morbidity and mortality
overall, there was a 28% reduction in the patients who were
not on beta-blockers and an 11% increase in those who were.
Thus, in Val-HeFT, three neurohormonal antagonists were
not better than two, but two appeared better than one.
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Recent drug development has focused on new agents that
modulate other neurohormonal systems or their potential
downstream consequences such as cytokine activation, ap-
optosis and remodeling. In the current treatment milieu,
most of these agents are being investigated in populations
with nearly universal treatment with blockers of the renin-
angiotensin system and a high proportion of beta-blocker
therapy. So far, the results have not been very encouraging.
Two endothelin receptor antagonists, bosentan and en-
rasentan, both of which have mixed ET-1a and ET-1b
activity, have been evaluated in phase II heart failure trials.
Bosentan was evaluated in 368 patients with NYHA func-
tional class IIIb or IV heart failure, all of whom were
receiving an ACE inhibitor or angiotensin receptor blocker
and 25% of whom were taking beta-blockers (26). Overall,
bosentan had a neutral effect in clinical end points, but this
appeared to reflect a higher incidence of early deterioration
in the bosentan groups and a reduction in events in the latter
half of the six-month follow-up period. Enrasentan was
assessed in 419 patients with NYHA functional class II or
III CHF on 5 to 10 mg of enalapril or the equivalent and,
in many cases, beta-blockers (27). They were randomized to
placebo or one of four doses of enrasentan. Although the
numbers of subjects in each group were small, there was a
strong trend toward less improvement and more deteriora-
tion in the enrasentan patients (p  0.06). Finally, a large
program evaluating the effect of the TNF-alpha binding
protein etanercept was recently discontinued because of lack
of benefit (27), again in a population in which patients were
generally receiving both renin-angiotensin system antago-
nists and beta-blockers.
These results suggest that more neurohormonal antago-
nism may not necessarily lead to better outcomes. Clearly, it
is too early to generalize, however, and until further infor-
mation is available, these findings need to be considered to
be specific to the agents utilized and the patient populations
in which they were studied. Nonetheless, because the trends
in several studies were toward worse outcomes with multiple
neurohormonal antagonists, caution is warranted in both
drug development and in the clinic. Indeed, excessive
blockade of the adrenergic nervous system has been cited as
a possible explanation for both the lesser benefit of bucin-
dolol in the Beta-blocker Evaluation of Survival Trial
(BEST) compared to other beta-blocker trials in heart
failure patients (28) and in the early termination of the
Moxonidine Congestive Heart Failure (MOXCON) trial
for worse outcomes (29), although other potential explana-
tions exist for both of these results.
IS MORE NEUROHORMONAL
ANTAGONISM NECESSARY? IS IT BETTER?
The results reviewed in this editorial have several important
implications. First, it should be emphasized that the use of
neurohormonal inhibitors represents the most important
advance in the treatment of heart failure since the advent of
diuretics. Both ACE inhibitors and beta-blockers are effec-
tive in improving survival, preventing progression of cardiac
dysfunction and improving clinical status. Both should be
used in patients with systolic dysfunction, unless not toler-
ated or otherwise contraindicated. The incremental benefit
of the combination is likely to outweigh the incremental
benefit of using higher doses of one.
Second, we lack adequate information to make definitive
recommendations concerning doses of these agents. The
study by Tang et al. (10) and the results of the ATLAS trial
(11) suggest that there may be an advantage for higher doses
of ACE inhibitors compared to low doses, but this advan-
tage may be relatively modest. Thus, the use of what now
can be considered moderate doses, those used in most
clinical trials (enalapril 10 to 20 mg or captopril 75 to 150 mg
or the equivalent) should be encouraged. The picture with
beta-blockers is not much clearer. Although one study (30) has
suggested that intermediate doses of a beta-blocker can be
beneficial, other trials using relatively low doses (the first
Cardiac Insufficiency Bisoprolol Study [CIBIS] and the
Metroprolol in Dilated Cardiomyopathy [MDC]) did not
demonstrate as impressive benefits as later trials using higher
doses of the same agents (31,32). The present recommenda-
tion must be to use agents and doses that have improved
survival—carvedilol 25 mg twice daily, metoprolol 150 to
200 mg daily or bisoprolol 10 mg daily.
Third, the addition of other neurohormonal antagonists
in patients already receiving an ACE inhibitor (or an
angiotensin receptor blocker in ACE-inhibitor-intolerant
patients) and a beta-blocker needs to considered on a
drug-by-drug basis and in relation to the characteristics of
the individual patient. Spironolactone appears to be bene-
ficial in patients with severe heart failure, but it may not be
either effective or safe in those with less severe symptoms or
lesser diuretic requirements. In contrast, there is no justifi-
cation for adding an angiotensin receptor blocker to patients
receiving both an ACE inhibitor and beta-blocker.
And finally, it is possible that the string of successes with
neurohormonal antagonists may have run its course. Al-
though the prognosis of heart failure patients remains poor
and neurohormonal activation persists despite treatment
with ACE inhibition, beta-blockers and spironolactone, the
presumption that the addition of other antagonists will be
effective cannot be taken for granted. Recent neutral or
negative results may reflect the difficulty of producing
additional blockade of relevant neurohormonal systems, the
selection of mechanistically unimportant targets or an ad-
verse effect of excessive blockade. Research in this area should
and will continue, with agents such as endothelin antagonists,
vasopressin antagonists and cytokine inhibitors. However, it is
also important to explore other therapeutic avenues, such as
drugs that improve myocardial energetics, oxygen-carrying
capacity and myocardial contractility or relaxation by novel
mechanisms, as well as devices that enhance myocardial per-
formance or prevent arrhythmic death.
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